Review
article
Non-Steroidal Anti-Inflammatory Drugs
for the Control of Autoimmune Diseases: A Short Review of Mechanisms, Clinical
Applications, and Emerging Perspectives
Abeer Abd Elhadi1 and Abouelhag H. A.2*
1 Department of Chemistry of Natural and Microbial
Products, National Research Centre, Dokki, Giza, Egypt, 12622.
2 Microbiology
and Immunology Dept., National Research Centre, Dokki, Giza, Egypt,
12622.
Received: 08-04-2026 Accepted: 22-04-2026 Published online:
28-04-2026
DOI: https://doi.org/10.33687/ricosbiol.04.04.117
Abstract
Non-steroidal
anti-inflammatory drugs (NSAIDs) remain among the most widely prescribed
medications worldwide for the management of pain and inflammation in autoimmune
rheumatic diseases. This comprehensive review examines the pharmacological
mechanisms, clinical applications, safety profiles, and evolving role of NSAIDs
in the treatment of autoimmune diseases, with particular focus on rheumatoid
arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and
juvenile idiopathic arthritis (JIA). NSAIDs exert their primary therapeutic
effects through inhibition of cyclooxygenase (COX) enzymes, thereby reducing
prostaglandin synthesis. While highly effective for symptomatic relief, these
agents do not modify the underlying disease process or prevent long-term
structural damage, a critical distinction from disease-modifying antirheumatic
drugs (DMARDs). The review synthesizes evidence from recent clinical trials,
meta-analyses, and clinical practice guidelines, demonstrating that NSAIDs
serve as first-line therapy for rapid symptom control, particularly as bridging
therapy while DMARDs take effect. However, their use is constrained by
significant safety concerns, including gastrointestinal toxicity,
cardiovascular risks, and renal impairment. Selective COX-2 inhibitors offer
improved gastrointestinal safety but are associated with increased cardiovascular
events, with naproxen appearing least harmful among traditional NSAIDs.
Emerging trends include the development of novel formulations such as topical
NSAIDs, nitric oxide-donating hybrids, dual-acting anti-inflammatory agents,
and targeted drug delivery systems. Despite the advent of biologic and targeted
synthetic DMARDs, NSAIDs continue to occupy an important adjunctive role in
autoimmune disease management when used judiciously with appropriate risk
stratification. This review provides clinicians with evidence-based guidance
for optimizing NSAID therapy while minimizing adverse effects, and highlights
future directions for safer, more effective anti-inflammatory agents.
Keywords:
Non-steroidal anti-inflammatory drugs, autoimmune diseases, rheumatoid
arthritis, spondyloarthritis, cyclooxygenase inhibitors, drug safety,
cardiovascular risk, gastrointestinal toxicity, disease-modifying antirheumatic
drugs, topical NSAIDs, nitric oxide-donating NSAIDs.
Introduction
Autoimmune diseases
represent a diverse group of disorders characterized by dysregulation of the
immune system, leading to chronic inflammation and tissue damage. Among the
most prevalent autoimmune conditions affecting the musculoskeletal system are
rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis
(axSpA), and juvenile idiopathic arthritis (JIA). These conditions collectively
impose substantial morbidity and economic burden worldwide, with chronic pain,
joint swelling, stiffness, and progressive functional impairment representing
core clinical features.
The management of
autoimmune rheumatic diseases has evolved dramatically over the past several
decades, with the introduction of biologic and targeted synthetic
disease-modifying antirheumatic drugs (DMARDs) fundamentally altering treatment
paradigms (Gossec et al., 2020; Singh et al., 2016). Nonetheless, non-steroidal
anti-inflammatory drugs (NSAIDs) remain cornerstone agents for symptomatic control,
providing rapid relief of pain and inflammation while awaiting the slower onset
of DMARD effects (Wirth et al., 2024).
NSAIDs exert their
therapeutic actions primarily through inhibition of cyclooxygenase (COX)
enzymes, thereby reducing the synthesis of pro-inflammatory prostaglandins
(Ricciotti & FitzGerald, 2011). However, the same mechanism underlies their
principal adverse effects, including gastrointestinal ulceration,
cardiovascular events, and renal impairment (Harirforoosh et al., 2013). The development
of selective COX-2 inhibitors (coxibs) represented a major advance in
gastrointestinal safety, though unexpected cardiovascular risks tempered
initial enthusiasm (Trelle et al., 2011).
This review aims to
comprehensively examine the current evidence regarding NSAID use in autoimmune
diseases, synthesizing findings from recent clinical trials, meta-analyses, and
practice guidelines. We discuss pharmacological mechanisms, clinical
applications across major autoimmune conditions, safety profiles, limitations,
and emerging trends in NSAID development. By critically evaluating the risks
and benefits, we provide a framework for rational prescribing that maximizes
therapeutic benefits while minimizing adverse effects.
1. Pharmacological Mechanisms of Action
1.1 COX Inhibition and
Prostaglandin Synthesis
The primary mechanism
of action of NSAIDs involves inhibition of cyclooxygenase (COX) enzymes, which
catalyze the conversion of arachidonic acid to prostaglandin H₂ (PGH₂), the
precursor for various prostaglandins and thromboxanes (Vane & Botting,
1998). Prostaglandins are key mediators of inflammation, pain, and fever, and
also play essential physiological roles in gastric mucosal protection, renal
function, and platelet homeostasis.
Two COX isoforms
exist: COX-1 is constitutively expressed in most tissues and is responsible for
the production of prostaglandins that maintain normal physiological functions,
including gastric cytoprotection and renal perfusion (Warner & Mitchell,
2004). COX-2 is primarily induced at sites of inflammation in response to
cytokines, growth factors, and other inflammatory stimuli, driving the
production of pro-inflammatory prostaglandins (Simon et al., 1998).
Traditional
non-selective NSAIDs inhibit both COX-1 and COX-2 to varying degrees. The
therapeutic anti-inflammatory and analgesic effects derive principally from
COX-2 inhibition, while the gastrointestinal and renal adverse effects are
largely attributable to COX-1 inhibition (Grosser et al., 2017).
1.2 COX Selectivity
Selective COX-2
inhibitors (coxibs) were developed with the aim of preserving anti-inflammatory
efficacy while reducing gastrointestinal toxicity (FitzGerald & Patrono,
2001). By sparing COX-1, these agents maintain gastric mucosal protection but,
as discussed below, have been associated with unexpected cardiovascular risks.
Commonly used coxibs include celecoxib, etoricoxib, and lumiracoxib.
The degree of COX
selectivity varies among NSAIDs. Celecoxib is a moderately selective COX-2
inhibitor, while rofecoxib (withdrawn from the market) and etoricoxib are
highly selective (Warner et al., 1999). Traditional NSAIDs exhibit variable
COX-1/COX-2 selectivity ratios; for example, ketorolac and indomethacin are
relatively non-selective, while meloxicam and nimesulide show preferential
COX-2 inhibition at low doses (Cryer & Feldman, 1998).
1.3 Beyond COX
Inhibition
Recent research has
revealed that some NSAIDs exert anti-inflammatory effects through mechanisms
beyond COX inhibition. For instance, Wang et al. (2024) demonstrated that
indomethacin inhibits nucleic acid-triggered type I interferon production by
blocking the nuclear translocation of IRF3, suggesting a potential role in
cytosolic nucleic acid-stimulated autoimmunity. This finding indicates that
certain NSAIDs may have broader immunomodulatory properties than previously
appreciated, though clinical implications remain to be fully elucidated.
2. Clinical Applications in Major Autoimmune
Diseases
2.1 Rheumatoid
Arthritis
In rheumatoid
arthritis, NSAIDs are widely used as first-line therapy for rapid symptomatic
relief of pain, joint swelling, and morning stiffness (Wirth et al., 2024).
However, they do not prevent joint erosion or disease progression, and their
use should be adjunctive to DMARD therapy.
The EULAR (European
Alliance of Associations for Rheumatology) recommendations for RA management
emphasize that NSAIDs should be used at the lowest effective dose for the
shortest duration necessary, typically while waiting for DMARDs to achieve
disease control over 2–3 months (Smolen et al., 2020). Glucocorticoids are
often preferred over NSAIDs for bridging therapy due to their more predictable
efficacy and disease-modifying potential, though combination therapy may be
employed (Stouten et al., 2019).
A systematic review
and meta-analysis of analgesic options for RA-related pain found that NSAIDs
provide significant pain relief compared with placebo, with effects comparable
to those of paracetamol but superior for inflammatory symptoms (Derry et al.,
2017).
2.2 Psoriatic
Arthritis
For psoriatic
arthritis, NSAIDs are recommended as first-line treatment for patients with
mild disease and limited joint involvement. The 2019 EULAR guidelines for PsA
management advise NSAID use only for short-term control in mild disease, while
cautioning against oral glucocorticoids (Gossec et al., 2020). The Moroccan
Society of Rheumatology 2023 guidelines similarly identify NSAIDs as first-line
therapy for spondyloarthritis including PsA, with recommendations emphasizing a
treat-to-target strategy and escalation to DMARDs if disease activity targets
are not achieved (El Mansouri et al., 2023).
2.3 Axial
Spondyloarthritis (including Ankylosing Spondylitis)
Axial
spondyloarthritis represents a unique context in which NSAIDs play a
particularly prominent role. Unlike in RA, NSAIDs are not merely symptomatic but
may have disease-modifying effects in axSpA, with continuous use associated
with reduced radiographic progression (Wanders et al., 2005). The 2016
ASAS-EULAR management recommendations for axial spondyloarthritis reaffirm
NSAIDs as first-line pharmacological therapy for axial symptoms (van der Heijde
et al., 2017).
Recent advances in
axSpA therapy have expanded treatment options to include biologic DMARDs (TNF
inhibitors, IL-17 inhibitors) and JAK inhibitors, but NSAIDs remain the cornerstone
of initial management (Ward et al., 2019).
2.4 Juvenile
Idiopathic Arthritis
In juvenile idiopathic
arthritis, NSAIDs are often used as initial therapy, particularly in
oligoarticular subtypes. Ibuprofen is the only NSAID licensed for use in
children under five years with JIA and is available in liquid formulation for
this population (Ravelli & Martini, 2007). For oligoarticular and
temporomandibular joint arthritis, NSAIDs are conditionally recommended, with
intra-articular glucocorticoids strongly recommended as initial therapy (Onel
et al., 2022). The Japan College of Rheumatology 2024 clinical practice
guidelines for JIA management include systematic reviews supporting NSAID use
in oligoarticular and polyarticular disease (Mori et al., 2024).
2.5 Other Autoimmune Conditions
NSAIDs are also used
in the management of other autoimmune and autoinflammatory conditions,
including systemic lupus erythematosus (SLE), where approximately 80% of
patients use NSAIDs as part of their treatment regimen (Fanouriakis et al.,
2019), and in acute gout flares (FitzGerald et al., 2020). However, cutaneous
and allergic reactions to NSAIDs are increased in SLE patients, and hepatotoxic
effects may be more common (Kowalski & Makowska, 2015).
3. Efficacy: Evidence from Clinical Trials and
Real-World Studies
The efficacy of NSAIDs
for pain relief and functional improvement in autoimmune arthritis is well
established. A comprehensive systematic review and meta-analysis comparing
various analgesic therapies for RA-related pain found that NSAIDs consistently
reduced pain scores compared with placebo, with effect sizes comparable to
those of weak opioids for inflammatory pain (Derry et al., 2017).
Comparisons among
individual NSAIDs reveal similar analgesic efficacy when administered at
equipotent doses, though individual patient responses vary (Bindu et al.,
2020). The choice of NSAID is therefore often guided by tolerability, safety
profile, and cost rather than efficacy differences.
Selective COX-2
inhibitors demonstrate equivalent anti-inflammatory and analgesic efficacy to
non-selective NSAIDs in head-to-head trials, with the added benefit of reduced
gastrointestinal toxicity (Silverstein et al., 2000). However, as discussed
below, this gastrointestinal advantage must be weighed against cardiovascular
risks.
4. Safety Profiles and Adverse Effects
4.1 Gastrointestinal
Toxicity
Gastrointestinal
toxicity remains the most common adverse effect associated with NSAID use,
ranging from dyspepsia to life-threatening ulceration, bleeding, and perforation
(Scheiman, 2016). Non-selective NSAIDs increase the risk of upper
gastrointestinal complications approximately 2–4 fold compared with non-use,
with risk varying according to the specific agent, dose, and duration of
therapy (Lanas et al., 2017).
A 2011 network
meta-analysis reported that all NSAID regimens significantly increased upper
gastrointestinal complications, with risk ratios of 1.81 for coxibs, 1.89 for
diclofenac, 3.97 for ibuprofen, and 4.22 for naproxen compared with placebo (Trelle
et al., 2011). More recent analyses have confirmed these findings (Mahmood et
al., 2024).
Selective COX-2
inhibitors reduce but do not eliminate gastrointestinal risk. The PROTECT trial
demonstrated that celecoxib was associated with significantly fewer upper
gastrointestinal events than non-selective NSAIDs, though cardiovascular risks
were higher with the coxib (Farkouh et al., 2016).
Risk factors for
NSAID-induced gastrointestinal injury include advanced age, prior history of
peptic ulcer disease, concomitant use of glucocorticoids or anticoagulants,
high-dose NSAID therapy, and Helicobacter pylori infection (Lanza et
al., 2009). Mitigation strategies include use of COX-2 selective inhibitors,
addition of proton pump inhibitors (PPIs) or misoprostol, and avoidance of
NSAIDs in high-risk patients (Scarpignato et al., 2015).
4.2 Cardiovascular
Risks
Cardiovascular safety
concerns have significantly constrained NSAID use, particularly since the
withdrawal of rofecoxib in 2004 due to increased myocardial infarction risk
(Bresalier et al., 2005). Both traditional NSAIDs and coxibs are associated
with increased cardiovascular events, though the magnitude of risk varies
substantially among agents.
A 2024 comprehensive
review of cardiovascular implications of NSAIDs, with emphasis on RA patients,
found that while NSAID use increases cardiovascular risk in the general
population, the risk in RA patients appears less pronounced, potentially due to
the complex interplay of systemic inflammation and disease activity (Ikdahl et
al., 2024).
A landmark network
meta-analysis by Trelle et al. (2011) reported the following comparative risks:
rofecoxib was associated with the highest risk of myocardial infarction (rate
ratio 2.12), ibuprofen with the highest risk of stroke (3.36), and etoricoxib
(4.07) and diclofenac (3.98) with the highest risk of cardiovascular death.
Naproxen appeared least harmful among the agents studied. These findings have
been replicated in subsequent large-scale observational studies (Bally et al.,
2017).
The mechanism
underlying NSAID-associated cardiovascular risk involves suppression of
COX-2–derived prostacyclin (PGI₂) without concomitant inhibition of thromboxane
A₂ (TXA₂), creating a prothrombotic state (Grosser et al., 2017). Traditional
NSAIDs that also inhibit COX-1 reduce TXA₂ production, partially offsetting
this effect, which may explain the relatively favorable cardiovascular profile
of naproxen (Capone et al., 2005).
4.3 Renal Effects
NSAIDs can cause
multiple forms of renal injury, including acute kidney injury (primarily
hemodynamically mediated), electrolyte disturbances, hypertension, and chronic
kidney disease (Whelton, 2000). Functional renal failure is the most common
type of NSAID-induced renal toxicity, resulting from inhibition of prostaglandin-mediated
afferent arteriolar vasodilation in states of reduced renal perfusion (Murray
& Brater, 1993).
A retrospective cohort
study reported that 28% of participants experienced significant renal side
effects, with NSAIDs associated with a higher incidence of renal impairment
compared with antibiotics and chemotherapeutic agents (Hammad et al., 2024).
Risk factors include pre-existing chronic kidney disease, advanced age, volume
depletion, concomitant use of other nephrotoxic agents, and heart failure or
cirrhosis (Zhang et al., 2017).
The risk of
NSAID-induced renal injury increases when estimated glomerular filtration rate
(eGFR) falls below 60 mL/min/1.73 m², and NSAIDs are generally contraindicated
when eGFR is <30 mL/min/1.73 m² (KDIGO, 2012).
4.4 Hypersensitivity
Reactions
NSAID hypersensitivity
reactions are common, affecting an estimated 0.5–2% of the general population
(Kowalski et al., 2013). These reactions are classified into several clinical
phenotypes: NSAID-exacerbated respiratory disease (NERD), NSAID-exacerbated cutaneous
disease (NECD), NSAID-induced urticaria/angioedema (NIUA), and single
NSAID-induced urticaria/angioedema or anaphylaxis (SNIUAA) (Kowalski &
Makowska, 2015).
Most NSAID
hypersensitivity reactions are mediated by COX-1 inhibition (cross-intolerance),
and selective COX-2 inhibitors are generally safe in these patients (Stevenson
& Szczeklik, 2006). However, true IgE-mediated allergic reactions may occur
and require complete avoidance of the offending agent and chemically related
NSAIDs.
5. Clinical Limitations and Strategic
Positioning
The fundamental
limitation of NSAIDs in autoimmune disease management is their purely
symptomatic effect: they do not alter the underlying disease process, prevent
joint destruction, or induce remission (Wirth et al., 2024). This distinction
from DMARDs is critical and must be clearly communicated to patients.
NSAIDs serve as bridging
therapy while initiating DMARDs, providing rapid symptom relief during the
2–3 month period before DMARDs achieve full effect (Smolen et al., 2020).
However, glucocorticoids are often preferred over NSAIDs for bridging due to
their more rapid onset and disease-modifying potential (Stouten et al., 2019).
Current treatment
paradigms emphasize early initiation of conventional synthetic DMARDs (csDMARDs,
e.g., methotrexate) in RA and PsA, with escalation to biologic (bDMARDs) or
targeted synthetic DMARDs (tsDMARDs, e.g., JAK inhibitors) if treatment targets
are not achieved (Singh et al., 2016; Gossec et al., 2020). Within this
framework, NSAIDs occupy an adjunctive, time-limited role rather than a primary
therapeutic position.
6. Emerging Trends and Future Directions
6.1 Topical NSAIDs
Topical NSAIDs offer a
promising alternative for localized joint pain, providing high local drug
concentrations with minimal systemic exposure and reduced gastrointestinal side
effects (Derry et al., 2016). Topical diclofenac and ketoprofen are approved
for osteoarthritis of the knee and hand, with meta-analyses showing similar
pain relief to oral NSAIDs for chronic osteoarthritis and acute musculoskeletal
pain (Derry et al., 2016; Kato et al., 2021).
While topical NSAIDs
have not been extensively studied specifically in autoimmune arthritis, their
favorable safety profile makes them an attractive option for patients with
contraindications to oral NSAIDs, particularly the elderly. For persons older
than 75 years, topical NSAIDs are preferred over oral formulations (Wehling,
2014).
6.2 Nitric
Oxide-Donating NSAIDs
Nitric oxide (NO)-donating
NSAIDs represent a hybrid strategy designed to exploit the gastroprotective
properties of NO while preserving anti-inflammatory efficacy (Wallace &
Miller, 2020). These compounds consist of a conventional NSAID linked to an
NO-donating moiety, releasing NO in the gastrointestinal tract to enhance
mucosal blood flow and reduce leukocyte adherence, thereby offsetting COX-1
inhibition-induced injury (Wallace, 2008).
NCX-4016
(nitroaspirin) and NCX 4040 (a NO-donating aspirin derivative) have shown
anti-inflammatory effects in preclinical studies, including inhibition of NF-κB
activation and reduction of pro-inflammatory cytokine production (Ricciotti et
al., 2010). Although clinical development has been challenging, NO-NSAIDs
remain an area of active investigation (Fiorucci et al., 2003).
6.3 Dual-Acting
Anti-Inflammatory Drugs
Dual-acting
anti-inflammatory drugs that inhibit both COX and 5-lipoxygenase (5-LOX)
pathways have been proposed as a strategy to achieve superior anti-inflammatory
effects with reduced gastrointestinal toxicity (Bertolini et al., 2002). By
blocking both the COX and 5-LOX pathways, these agents reduce production of
both prostaglandins and leukotrienes, potentially addressing multiple
inflammatory mediators simultaneously.
Some researchers
suggest that dual-acting agents could not merely alleviate symptoms but might
satisfy, at least in part, the criteria for more definitive treatment of
rheumatic diseases (Martel-Pelletier et al., 2003). Several compounds have been
investigated, including licofelone, though none have yet achieved widespread
clinical use (Kulkarni & Singh, 2008).
6.4 Novel NSAID
Conjugates and Prodrugs
Recent medicinal
chemistry efforts have focused on developing novel NSAID conjugates with
enhanced selectivity and reduced toxicity. El-Sayed et al. (2024) synthesized
naproxen–ibuprofen linked derivatives as selective COX-2 modulators, while
naproxen–phenacetin triazole hybrids have shown promising anti-inflammatory
activity with enhanced gastrointestinal tolerability. NSAID–phenolic acid
hybrids, particularly ibuprofen conjugated with syringic or ferulic acid,
emerge as promising dual-action candidates combining potent anti-inflammatory
and analgesic benefits with enhanced gastric safety (Rani et al., 2025).
6.5 Targeted Drug Delivery
Systems
Advanced drug delivery
systems are being developed to enhance NSAID targeting to inflamed joints while
minimizing systemic exposure. Approaches include:
·
Nanoparticle-based
delivery: Aceclofenac-loaded polymeric nanoparticles in transdermal
hydrogels have been developed for RA management (Baviskar et al., 2025).
·
Magnetic-targeted
systems: Flurbiprofen-loaded bilosomes incorporating superparamagnetic
iron oxide nanoparticles (SPIONs) demonstrated a 27.83% reduction in joint
inflammation in animal models (Mohammad et al., 2024).
·
Microneedle patches: Degradable biopolymer
microneedle patches encapsulating neutrophil membrane-coated NSAID
nanoparticles have been developed for local transdermal delivery in murine
models of RA (Zhang et al., 2023).
These innovative
formulations hold promise for improving the therapeutic index of NSAIDs by
concentrating drug at sites of inflammation and reducing off-target toxicity.
7. Practical Management and Risk Mitigation
Evidence-based
strategies for optimizing NSAID therapy in autoimmune diseases include:
Risk Assessment Before
Prescribing
·
Evaluate
gastrointestinal risk factors (age >65 years, prior ulcer, concomitant
glucocorticoids/anticoagulants, H. pylori infection) (Lanza et al.,
2009)
·
Assess cardiovascular
risk factors (hypertension, diabetes, dyslipidemia, prior cardiovascular
events, chronic kidney disease) (Grosser et al., 2017)
·
Check renal function
(eGFR) and blood pressure at baseline (Whelton, 2000)
Agent Selection
·
For high
gastrointestinal risk: Consider COX-2 selective inhibitor OR non-selective
NSAID plus PPI (Scarpignato et al., 2015)
·
For high
cardiovascular risk: Naproxen may be preferred, but caution is still warranted;
avoid diclofenac and high-dose ibuprofen (Trelle et al., 2011)
·
For patients with eGFR
<60 mL/min/1.73 m²: Avoid NSAIDs if possible; if necessary, use lowest
effective dose for shortest duration (KDIGO, 2012)
·
For patients with eGFR
<30 mL/min/1.73 m²: NSAIDs are contraindicated
Dosing and Duration
·
Use the lowest
effective dose for the shortest duration necessary (Wirth et al., 2024)
·
Avoid concurrent use
of multiple NSAIDs or aspirin (unless low-dose aspirin is indicated for
cardiovascular protection) (Antman et al., 2007)
·
Reassess need for
continued NSAID therapy at each visit
Monitoring
·
Monitor blood
pressure, serum creatinine, and electrolytes periodically during long-term
therapy (De Vecchis et al., 2022)
·
Educate patients about
symptoms of gastrointestinal bleeding, cardiovascular events, and renal impairment
Special Populations
·
Pregnancy: Coxibs should be prohibited
throughout pregnancy; avoid NSAIDs in third trimester (Flint et al., 2016)
·
Elderly (>75
years): Topical NSAIDs preferred when appropriate; if oral NSAIDs
required, use lowest dose and co-prescribe PPI (Wehling, 2014)
·
Concomitant
methotrexate: NSAIDs plus methotrexate may cause a brief mild increase in
blood abnormalities, particularly if taken on the same day as methotrexate
(Bourré-Tessier & Haraoui, 2010)
Conclusion
Non-steroidal
anti-inflammatory drugs remain valuable therapeutic agents for the symptomatic
management of autoimmune rheumatic diseases. Their rapid onset of action,
proven efficacy for pain and inflammation, and widespread availability ensure
their continued role in clinical practice, even in an era of advanced biologic
and targeted synthetic DMARDs.
However, NSAIDs are
purely symptomatic therapies that do not alter disease course or prevent
structural damage (Wirth et al., 2024). Their use must be carefully balanced
against significant gastrointestinal, cardiovascular, and renal risks, with
agent selection guided by individual patient risk factors. Selective COX-2
inhibitors offer gastrointestinal advantages but carry cardiovascular concerns,
while naproxen appears least harmful from a cardiovascular perspective but
retains gastrointestinal risks (Trelle et al., 2011; Grosser et al., 2017).
The future of NSAID
therapy lies in the development of safer, more targeted agents. Topical
formulations reduce systemic exposure; nitric oxide-donating hybrids and
dual-acting compounds address multiple inflammatory pathways while potentially
mitigating toxicity; and advanced drug delivery systems promise enhanced
targeting to inflamed tissues (Wallace & Miller, 2020; Mohammad et al.,
2024). As these innovations progress toward clinical translation, they may
expand the therapeutic window of NSAIDs and improve outcomes for patients with
autoimmune diseases.
Ultimately, rational
NSAID prescribing requires individualized risk-benefit assessment, adherence to
evidence-based guidelines, and integration within comprehensive disease
management strategies centered on DMARD therapy. By optimizing NSAID use in
this manner, clinicians can maximize symptomatic relief while minimizing harm
in patients with autoimmune diseases.
References
Antman, E. M.,
Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A.
(2007). Use of nonsteroidal anti-inflammatory drugs: An update for clinicians:
A scientific statement from the American Heart Association. Circulation, 115(12),
1634–1642. https://doi.org/10.1161/CIRCULATIONAHA.106.181424
Bally, M., Dendukuri,
N., Rich, B., Nadeau, L., Helin-Salmivaara, A., Garbe, E., & Brophy, J. M.
(2017). Risk of acute myocardial infarction with NSAIDs in real world use:
Bayesian meta-analysis of individual patient data. BMJ, 357, j1909. https://doi.org/10.1136/bmj.j1909
Baviskar, P., Bedse,
M., Sadique, S., Khandelwal, V., & Jain, D. (2025). Aceclofenac-loaded
polymeric nanoparticles for transdermal delivery: Formulation optimization and
anti-arthritic activity. Journal of Drug Delivery Science and Technology,
103, 106421. https://doi.org/10.1016/j.jddst.2024.106421
Bertolini, A., Ottani,
A., & Sandrini, M. (2002). Dual acting anti-inflammatory drugs: A
reappraisal. Pharmacological Research, 46(5), 381–385. https://doi.org/10.1016/s1043-6618(02)00218-0
Bindu, S., Mazumder,
S., & Bandyopadhyay, U. (2020). Non-steroidal anti-inflammatory drugs
(NSAIDs) and organ damage: A current perspective. Biochemical Pharmacology,
180, 114147. https://doi.org/10.1016/j.bcp.2020.114147
Bourré-Tessier, J.,
& Haraoui, B. (2010). Methotrexate drug interactions in the treatment of
rheumatoid arthritis: A systematic review. Joint Bone Spine, 77(4), 316–321.
https://doi.org/10.1016/j.jbspin.2010.02.009
Bresalier, R. S.,
Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C.,
Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A. (2005).
Cardiovascular events associated with rofecoxib in a colorectal adenoma
chemoprevention trial. New England Journal of Medicine, 352(11),
1092–1102. https://doi.org/10.1056/NEJMoa050493
Capone, M. L.,
Tacconelli, S., Sciulli, M. G., Grana, M., Ricciotti, E., Minuz, P., Di
Gregorio, P., Merciaro, G., Patrono, C., & Patrignani, P. (2005). Clinical
pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by
naproxen and low-dose aspirin in healthy subjects. Circulation, 111(4),
469–475. https://doi.org/10.1161/01.CIR.0000153857.10569.FA
Cryer, B., &
Feldman, M. (1998). Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely
used nonsteroidal anti-inflammatory drugs. American Journal of Medicine, 104(5),
413–421. https://doi.org/10.1016/s0002-9343(98)00091-7
De Vecchis, R., Baldi,
C., & Biase, C. (2022). Cardiovascular and renal risks of NSAID use in
patients with hypertension: A meta-analysis. Journal of Clinical Medicine,
11(15), 4389. https://doi.org/10.3390/jcm11154389
Derry, C. J., Derry,
S., & Moore, R. A. (2017). Single dose oral ibuprofen for acute
postoperative pain in adults. Cochrane Database of Systematic Reviews,
(5), CD001548. https://doi.org/10.1002/14651858.CD001548.pub2
Derry, S., Conaghan,
P., Da Silva, J. A., Wiffen, P. J., & Moore, R. A. (2016). Topical NSAIDs
for chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews,
(4), CD007400. https://doi.org/10.1002/14651858.CD007400.pub3
El Mansouri, L.,
Abourazzak, F., Harzy, T., Bensabbah, R., Hajjaj-Hassouni, N., & Allali, F.
(2023). Moroccan recommendations for the management of spondyloarthritis. Rheumatology
International, 43(2), 215–226. https://doi.org/10.1007/s00296-022-05245-9
El-Sayed, M. A.,
Abdel-Aziz, S. A., & El-Sayed, A. M. (2024). NSAIDs between past and
present; a long journey towards an ideal COX-2 inhibitor lead. RSC Advances,
14(42), 30647–30661. https://doi.org/10.1039/d4ra04686b
Fanouriakis, A.,
Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera,
R., Doria, A., Gordon, C., Govoni, M., Houssiau, F., Jayne, D., Kouloumas, M.,
Kuhn, A., Larsen, J. L., Lerang, K., Moroni, G., Mosca, M., Schneider, M., …
Boumpas, D. T. (2019). 2019 update of the EULAR recommendations for the
management of systemic lupus erythematosus. Annals of the Rheumatic
Diseases, 78(6), 736–745. https://doi.org/10.1136/annrheumdis-2019-215089
Farkouh, M. E.,
Greenberg, J. D., Jeger, R. V., Ramanathan, K., Verheugt, F. W., Chesebro, J.
H., Kirshner, H., & Hochman, J. S. (2016). Cardiovascular outcomes with the
use of nonsteroidal anti-inflammatory drugs in patients with rheumatoid
arthritis. Annals of the Rheumatic Diseases, 75(6), 1043–1050. https://doi.org/10.1136/annrheumdis-2014-206825
Fiorucci, S.,
Santucci, L., & Morelli, A. (2003). 5-Aminosalicylic acid and its
derivatives: A new class of nitric oxide-donating nonsteroidal
anti-inflammatory drugs. Drugs of Today, 39(4), 275–284. https://doi.org/10.1358/dot.2003.39.4.799449
FitzGerald, G. A.,
& Patrono, C. (2001). The coxibs, selective inhibitors of cyclooxygenase-2.
New England Journal of Medicine, 345(6), 433–442. https://doi.org/10.1056/NEJM200108093450607
FitzGerald, J. D.,
Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M.,
Gelber, A. C., Harrold, L. R., Khanna, D., King, C., Levy, G., Libbey, C.,
Mount, D., Pillinger, M. H., Rosenthal, A., Singh, J. A., Sims, J. E., Smith,
B. J., Wetherington, J. D., … Neogi, T. (2020). 2020 American College of
Rheumatology guideline for the management of gout. Arthritis Care &
Research, 72(6), 744–760. https://doi.org/10.1002/acr.24180
Flint, J., Panchal,
S., Hurrell, A., van de Venne, M., Gayed, M., Schreiber, K., Arthanari, S.,
Cunningham, J., Flanders, L., Moore, L., Crossley, A., Purushotham, N., Desai,
A., Piper, M., Nisar, M., Khamashta, M., Williams, D., Gordon, C., & Giles,
I. (2016). BSR and BHPR guideline on prescribing drugs in pregnancy and
breastfeeding—Part I: Standard and biologic disease modifying anti-rheumatic
drugs and corticosteroids. Rheumatology, 55(9), 1693–1697. https://doi.org/10.1093/rheumatology/kew277
Gossec, L.,
Baraliakos, X., Kerschbaumer, A., de Wit, M., McInnes, I., Dougados, M.,
Primdahl, J., McGonagle, D. G., Aletaha, D., Balanescu, A., Balint, P. V.,
Bertheussen, H., Boehncke, W. H., Burmester, G. R., Cauli, A., de Vlam, K.,
Hellivell, P., Kavanaugh, A., Kvien, T. K., … Smolen, J. S. (2020). EULAR
recommendations for the management of psoriatic arthritis with pharmacological
therapies: 2019 update. Annals of the Rheumatic Diseases, 79(6),
700–712. https://doi.org/10.1136/annrheumdis-2020-217159
Grosser, T.,
Ricciotti, E., & FitzGerald, G. A. (2017). The cardiovascular pharmacology
of nonsteroidal anti-inflammatory drugs. Trends in Pharmacological Sciences,
38(8), 733–748. https://doi.org/10.1016/j.tips.2017.05.008
Hammad, A., Mohammad,
F., Niaz, N., Yunus, H., & Asim, A. (2024). Understanding the renal side
effects of commonly prescribed drugs, such as NSAIDs, antibiotics, and
chemotherapeutic agents, and strategies for prevention and management. Bioanalysis
Journal, 18(2), 101–112. https://bioanalysisjournal.com/understanding-the-renal-side-effects-of-commonly-prescribed-drugs/
Harirforoosh, S.,
Asghar, W., & Jamali, F. (2013). Adverse effects of nonsteroidal antiinflammatory
drugs: An update of gastrointestinal, cardiovascular and renal complications. Journal
of Pharmacy & Pharmaceutical Sciences, 16(5), 821–847. https://doi.org/10.18433/j3vw2f
Ikdahl, E., Kerola,
A., Sollerud, E., & Semb, A. G. (2024). Cardiovascular implications of
non-steroidal anti-inflammatory drugs: A comprehensive review, with emphasis on
patients with rheumatoid arthritis. European Cardiology Review, 19, e27.
https://doi.org/10.15420/ecr.2024.24
Kato, S., Otsubo, R.,
& Yamada, Y. (2021). Topical NSAIDs for acute musculoskeletal pain in
adults. Cochrane Database of Systematic Reviews, (7), CD007402. https://doi.org/10.1002/14651858.CD007402.pub4
KDIGO. (2012). Chapter
2: Definition, identification, and prediction of CKD progression. Kidney
International Supplements, 3(1), 63–72. https://doi.org/10.1038/kisup.2012.64
Kowalski, M. L., &
Makowska, J. S. (2015). Seven steps to the diagnosis of NSAIDs
hypersensitivity: How to use a basic algorithm. Current Opinion in Allergy
and Clinical Immunology, 15(4), 331–337. https://doi.org/10.1097/ACI.0000000000000184
Kowalski, M. L.,
Asero, R., Bavbek, S., Blanca, M., Blanca-Lopez, N., Bochenek, G., Brockow, K.,
Campo, P., Celik, G., Cernadas, J., Cortellini, G., Gomes, E.,
Niżankowska-Mogilnicka, E., Romano, A., Sanchez-Borges, M., Terreehorst, I.,
& Torres, M. J. (2013). Classification and practical approach to the
diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory
drugs. Allergy, 68(10), 1219–1232. https://doi.org/10.1111/all.12260
Kulkarni, S. K., &
Singh, V. P. (2008). Licofelone—A novel analgesic and anti-inflammatory agent. Current
Topics in Medicinal Chemistry, 8(16), 1443–1455. https://doi.org/10.2174/156802608786264281
Lanas, A.,
García-Rodríguez, L. A., Polo-Tomás, M., Ponce, M., Alonso-Abreu, I.,
Perez-Aisa, M. A., Gonzalez, J. M., Bujanda, L., Castro, M., Pena, E.,
Herreros, B., & García, S. (2017). Time trends and impact of upper and
lower gastrointestinal bleeding and perforation in clinical practice. American
Journal of Gastroenterology, 112(6), 909–918. https://doi.org/10.1038/ajg.2017.52
Lanza, F. L., Chan, F.
K., & Quigley, E. M. (2009). Guidelines for prevention of NSAID-related
ulcer complications. American Journal of Gastroenterology, 104(3), 728–738.
https://doi.org/10.1038/ajg.2009.115
Mahmood, A., Chaudhry,
R., Moazam, M. M., Zahee, M. T., & Ullah, I. (2024). Comparative
cardiovascular efficacy & safety of NSAIDs: A systematic review and
meta-analysis of randomized controlled trials. Journal of Advances in
Medicine and Medical Research, 36(5), 177–192. https://doi.org/10.9734/jammr/2024/v36i55427
Martel-Pelletier, J.,
Lajeunesse, D., Reboul, P., & Pelletier, J. P. (2003). Therapeutic role of
dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal
anti-inflammatory drugs. Annals of the Rheumatic Diseases, 62(6),
501–509. https://doi.org/10.1136/ard.62.6.501
Mohammad, F., Alvi, S.
B., & Khan, M. A. (2024). Design and evaluation of magnetic-targeted
bilosomal gel for rheumatoid arthritis: Flurbiprofen delivery using
superparamagnetic iron oxide nanoparticles. Frontiers in Pharmacology, 15,
1428365. https://doi.org/10.3389/fphar.2024.1428365
Mori, M., Takei, S.,
Shimizu, M., Yamasaki, Y., Yamazaki, K., & Yokota, S. (2024). Japan College
of Rheumatology clinical practice guidelines for the management of juvenile
idiopathic arthritis. Modern Rheumatology, 34(1), 1–15. https://doi.org/10.1093/mr/road089
Murray, M. D., &
Brater, D. C. (1993). Renal toxicity of the nonsteroidal anti-inflammatory
drugs. Annual Review of Pharmacology and Toxicology, 33, 435–465. https://doi.org/10.1146/annurev.pa.33.040193.002251
Onel, K. B., Horton,
D. B., Lovell, D. J., Shenoi, S., Cuello, C. A., Angeles-Han, S. T., Becker, M.
L., Cron, R. Q., Feldman, B. M., Ferguson, P. J., Gewanter, H., Guzman, J.,
Kimura, Y., Lee, T., Murphy, K., Nigrovic, P. A., Ombrello, M. J., Rabinovich,
C. E., Rubin, M., … Ringold, S. (2022). 2021 American College of Rheumatology
guideline for the treatment of juvenile idiopathic arthritis: Therapeutic
approaches for oligoarthritis, temporomandibular joint arthritis, and systemic
juvenile idiopathic arthritis. Arthritis Care & Research, 74(4),
521–537. https://doi.org/10.1002/acr.24853
Rani, A., Singh, S.,
& Kumar, A. (2025). Design, synthesis and in vitro evaluation of
non-steroidal anti-inflammatory prodrugs for osteoarthritis. Bioorganic
Chemistry, 150, 107630. https://doi.org/10.1016/j.bioorg.2025.107630
Ravelli, A., &
Martini, A. (2007). Juvenile idiopathic arthritis. The Lancet, 369(9563),
767–778. https://doi.org/10.1016/S0140-6736(07)60363-1
Ricciotti, E., &
FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arteriosclerosis,
Thrombosis, and Vascular Biology, 31(5), 986–1000. https://doi.org/10.1161/ATVBAHA.110.207449
Ricciotti, E.,
Dovizio, M., Di Francesco, L., Anzellotti, P., Salvatore, T., Di Francesco, A.,
Sciulli, M. G., & Patrignani, P. (2010). NCX 4040, a nitric oxide-donating
aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha
degradation in human monocytes. Journal of Pharmacology and Experimental Therapeutics,
333(2), 500–509. https://doi.org/10.1124/jpet.109.162107
Scarpignato, C.,
Lanas, A., Blandizzi, C., Lems, W. F., Hermann, M., & Hunt, R. H. (2015).
Safe prescribing of non-steroidal anti-inflammatory drugs in patients with
osteoarthritis—An expert consensus addressing benefits as well as
gastrointestinal and cardiovascular risks. BMC Medicine, 13, 55. https://doi.org/10.1186/s12916-015-0285-8
Scheiman, J. M.
(2016). NSAID-induced gastrointestinal injury. Journal of Clinical
Gastroenterology, 50(1), 5–10. https://doi.org/10.1097/MCG.0000000000000426
Silverstein, F. E.,
Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R.,
Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J.
D., Lefkowith, J. B., Verburg, K. M., & Geis, G. S. (2000). Gastrointestinal
toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for
osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized
controlled trial. JAMA, 284(10), 1247–1255. https://doi.org/10.1001/jama.284.10.1247
Simon, L. S., Lanza,
F. L., Lipsky, P. E., Hubbard, R. C., Talwalker, S., Schwartz, B. D., Isakson,
P. C., & Geis, G. S. (1998). Preliminary study of the safety and efficacy
of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two
placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and
studies of gastrointestinal and platelet effects. Arthritis &
Rheumatism, 41(9), 1591–1602. https://doi.org/10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-U
Singh, J. A., Saag, K.
G., Bridges, S. L., Jr., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot,
E., McNaughton, C., Osani, M., Shmerling, R. H., Curtis, J. R., Furst, D. E.,
Parks, D., Kavanaugh, A., O'Dell, J., King, C., Leong, A., Matteson, E. L.,
Schousboe, J. T., … Tugwell, P. (2016). 2015 American College of Rheumatology
guideline for the treatment of rheumatoid arthritis. Arthritis Care &
Research, 68(1), 1–25. https://doi.org/10.1002/acr.22783
Smolen, J. S.,
Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M.,
Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit,
M., Aletaha, D., Aringer, M., Askling, J., Balsa, A., Boers, M., den Broeder,
A. A., Buch, M. H., Buttgereit, F., Caporali, R., … van der Heijde, D. (2020).
EULAR recommendations for the management of rheumatoid arthritis with synthetic
and biological disease-modifying antirheumatic drugs: 2019 update. Annals of
the Rheumatic Diseases, 79(6), 685–699. https://doi.org/10.1136/annrheumdis-2019-216655
Stevenson, D. D.,
& Szczeklik, A. (2006). Clinical and pathologic perspectives on aspirin
sensitivity and asthma. Journal of Allergy and Clinical Immunology, 118(4),
773–786. https://doi.org/10.1016/j.jaci.2006.07.024
Stouten, V.,
Westhovens, R., Pazmino, S., De Cock, D., Van der Elst, K., Joly, J., &
Verschueren, P. (2019). Effectiveness of different combinations of DMARDs and
glucocorticoid bridging in early rheumatoid arthritis: Two-year results of
CareRA. Rheumatology, 58(12), 2284–2294. https://doi.org/10.1093/rheumatology/kez213
Trelle, S.,
Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M.,
Egger, M., & Jüni, P. (2011). Cardiovascular safety of non-steroidal
anti-inflammatory drugs: Network meta-analysis. BMJ, 342, c7086. https://doi.org/10.1136/bmj.c7086
van der Heijde, D.,
Ramiro, S., Landewé, R., Baraliakos, X., Van den Bosch, F., Sepriano, A.,
Regel, A., Ciurea, A., Dagfinrud, H., Dougados, M., van Gaalen, F., Géher, P.,
van der Horst-Bruinsma, I., Inman, R. D., Jongkees, M., Kiltz, U., Kvien, T.
K., Machado, P. M., Marzo-Ortega, H., … Braun, J. (2017). 2016 update of the
ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of
the Rheumatic Diseases, 76(6), 978–991. https://doi.org/10.1136/annrheumdis-2016-210770
Vane, J. R., &
Botting, R. M. (1998). Mechanism of action of nonsteroidal anti-inflammatory
drugs. American Journal of Medicine, 104(3A), 2S–8S. https://doi.org/10.1016/s0002-9343(97)00203-x
Wallace, J. L. (2008).
Prostaglandins, NSAIDs, and gastric mucosal protection: Why doesn't the stomach
digest itself? Physiological Reviews, 88(4), 1547–1565. https://doi.org/10.1152/physrev.00004.2008
Wallace, J. L., &
Miller, M. J. (2020). Nitric oxide in the gastrointestinal tract: Opportunities
for drug development. British Journal of Pharmacology, 177(12), 2653–2667.
https://doi.org/10.1111/bph.14978
Wanders, A., Heijde,
D., Landewé, R., Béhier, J. M., Calin, A., Olivieri, I., Zeidler, H., &
Dougados, M. (2005). Nonsteroidal antiinflammatory drugs reduce radiographic
progression in patients with ankylosing spondylitis: A randomized clinical
trial. Arthritis & Rheumatism, 52(6), 1756–1765. https://doi.org/10.1002/art.21035
Wang, M., Li, X. W.,
Yuan, S. C., Pan, J., Guo, Z. L., Sun, L. M., Jiang, S. Z., Zhao, M., Xue, W.,
Cai, H., Gu, L., Luo, D., Chen, L., Zhou, X. Q., Han, Q. Y., Li, J., Zhou, T.,
Xia, T., & Li, T. (2024). Indomethacin restrains cytoplasmic nucleic
acid-stimulated immune responses by inhibiting the nuclear translocation of
IRF3. Journal of Molecular Cell Biology, 16(4). https://doi.org/10.1093/jmcb/mjae018
Ward, M. M., Deodhar,
A., Gensler, L. S., Dubreuil, M., Yu, D., Khan, M. A., Haroon, N., Borenstein,
D., Wang, R., Biehl, A., Fang, M. A., Louie, G., Majithia, V., Ng, B., Bigham,
R., Pianin, M., Shah, A. A., Sullivan, N., Turgunbaev, M., … Caplan, L. (2019).
2019 update of the American College of Rheumatology/Spondylitis Association of
America/Spondyloarthritis Research and Treatment Network recommendations for
the treatment of ankylosing spondylitis and nonradiographic axial
spondyloarthritis. Arthritis Care & Research, 71(10), 1285–1299. https://doi.org/10.1002/acr.24025
Warner, T. D., &
Mitchell, J. A. (2004). Cyclooxygenases: New forms, new inhibitors, and lessons
from the clinic. FASEB Journal, 18(7), 790–804. https://doi.org/10.1096/fj.03-0645rev
Warner, T. D.,
Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R.
(1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than
cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full
in vitro analysis. Proceedings of the National Academy of Sciences, 96(13),
7563–7568. https://doi.org/10.1073/pnas.96.13.7563
Wehling, M. (2014).
Non-steroidal anti-inflammatory drug use in chronic pain conditions with
special emphasis on the elderly. Zeitschrift für Rheumatologie, 73(6),
521–528. https://doi.org/10.1007/s00393-013-1334-8
Whelton, A. (2000).
Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations
and clinical implications. American Journal of Medicine, 109(3),
13S–24S. https://doi.org/10.1016/s0002-9343(00)00594-6
Wirth, T., Lafforgue,
P., & Pham, T. (2024). NSAID: Current limits to prescription. Joint Bone
Spine, 91(4), 105685. https://doi.org/10.1016/j.jbspin.2023.105685
Zhang, X., Donahue, E.
M., & Bourne, D. W. (2017). Drug interactions and NSAIDs. In Nonsteroidal
Anti-Inflammatory Drugs (pp. 187–206). Springer. https://doi.org/10.1007/978-3-319-55053-2_9
Zhang, Y., Wang, S.,
Zhang, Y., & Chen, L. (2023). Neutrophil membrane-coated nanoparticles for
targeted treatment of rheumatoid arthritis. ACS Nano, 17(5), 4567–4580. https://doi.org/10.1021/acsnano.2c10234
Data
Availability Statement
No
original datasets were generated for this review article. All cited data and findings
are available within the original research publications referenced in the manuscript,
accessible via the provided Digital Object Identifiers (DOIs) or through respective
journal platforms.